BioMarker Strategies Announces Publication of Research to Identify Dynamic Biomarkers to Better Predict and Improve Response to Cetuximab in Patients With Head and Neck/Esophageal Squamous Cell Carcinoma
ROCKVILLE, Maryland, August 09, 2022–(BUSINESS WIRE)–BioMarker Strategies today announced that the journal CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS has published a manuscript authored by Company scientists entitled “Functional Profiling of Head and Neck/Esophageal Squamous Cell Carcinoma to Predict Cetuximab Response”. The manuscript describes the company’s progress in identifying predictive dynamic biomarkers to help identify the subset of patients with head and neck/esophageal squamous cell carcinoma (SCC) who may benefit from treatment. by cetuximab (Erbitux) and biosimilars.
Cetuximab is an antibody that targets an epidermal growth factor receptor (EGFR) and remains the only U.S. Food and Drug Administration (FDA)-approved targeted therapy for head and neck/esophageal CTS. For primary SCC, cetuximab is approved for use in combination with radiation therapy. In metastatic SCC, it is approved for use in combination with platinum-based chemotherapy and fluorouracil.
The authors note that responses to cetuximab can be dramatic, but the response rate was only about 15% in the landmark clinical trial. The authors also note that treatment with cetuximab is associated with a risk of serious adverse events that lead to discontinuation of treatment in 3 to 10% of patients. The cost of treatment is approximately $100,000 per patient. Additionally, Immune Checkpoint Inhibitors are now an option in CSC. Therefore, methods to identify patients most likely to respond to cetuximab are needed.
SCC is the sixth most common cancer in the world. Worldwide, there are approximately 900,000 new cases and 450,000 deaths per year. In the United States alone, there are approximately 66,630 new cases and 14,620 deaths per year.
“To minimize the risks and maximize the therapeutic benefit of cetuximab, predictive tests to better identify patients likely to respond to treatment with cetuximab are clearly an important need,” said Jerry Parrott, president and CEO of BioMarker Strategies. . “From my perspective, based on the results reported here, I would agree with the authors that further studies are warranted to test more complex samples, including patient-derived tumor tissue.”
The research described in the manuscript discussed here was supported by a Small Business Innovation Research (SBIR) award from the National Cancer Institute (NCI) of the National Institutes of Health (NIH).
About BioMarker Strategies
BioMarker Strategies developed SnapPath®the only cancer diagnostic system that automates and standardizes ex-vivo profiling live solid tumor cells from fresh biopsies or other unfixed fresh samples such as patient-derived xenografts. SnapPath® can help guide cancer drug development and treatment selection. SnapPath® is unique in automating and standardizing the functional profiling of living solid tumor cells from fresh, unfixed tissue samples – and enables the generation of PathMAPs® Functional signaling profiles.
PathMAP® Functional signaling profiles, such as the studies described here, represent a new class of biomarker assays, which are based on the dynamic and predictive signaling information available only from living cells. They are useful for identifying and understanding mechanisms of acquired resistance, and they are highly predictive of individual tumor response to targeted therapies.
The information in this press release includes our projections and other forward-looking statements regarding future events. In some instances, forward-looking statements may be identified by words such as “may”, “will”, “should”, “expect”, “intend”, “plan”, “anticipate”, “believes”, “projects”, “estimates”, “predicts”, “potential”, “continues”, etc. These statements are not guarantees of future performance or achievement and involve certain risks and uncertainties, which are difficult to therefore, actual future results and trends may differ materially from what is projected herein.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220809005989/en/
Jerry Parrott, BioMarker Strategies, LLC